Although heart transplantation can drastically improve the survival of severe heart failure patients, the shortage of the donor heart is a serious problem and the regenerative medicine of the failing heart had been long awaited.
Dr. Keiichi Fukuda, who first reported that bone marrow mesenchymal stem cells (MSCs) could differentiate into cardiomyocytes (CMs) in vitro in 1999, founded Heartseed Inc. to put his research results of cardiac regenerative medicine into practice.
Our approach is to transplant sufficient number of CMs that electromechanically couple with patient’s heart. We’ve overcome technical challenges including differentiation from iPSCs, lager-scale manufacturing, purification and injection method.
The transplanted CMs showed physiological cell hypertrophy after transplantation and improved cardiac function in animal models without forming teratoma. We are planning to initiate FIH led by Keio Univ. in 2019 and Ph1/2 trial for patients with HFrEF in Japan in late 202
Session ID: 552813